ANI Pharmaceuticals ANIP Generics and Other — Research and Development expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's generics and other — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's generics and other — research and development expense?
- ANI Pharmaceuticals (ANIP) reported generics and other — research and development expense of $7.79M in Q1 2026.
- How has ANI Pharmaceuticals's generics and other — research and development expense changed year-over-year?
- ANI Pharmaceuticals's generics and other — research and development expense increased by 18.2% year-over-year, from $6.59M to $7.79M.
- What is the long-term trend for ANI Pharmaceuticals's generics and other — research and development expense?
- Over 3 years (2022 to 2025), ANI Pharmaceuticals's generics and other — research and development expense has grown at a 22.6% compound annual growth rate (CAGR), from $19.96M to $36.82M.
- What does generics and other — research and development expense mean?
- Captures the costs incurred for the research, development, and clinical testing of new generic formulations or complex pharmaceutical products within this segment. This investment reflects the company's commitment to pipeline expansion and its ability to bring new, high-value products to market.